INTRODUCTION
One explanation proposed for the relative lack of progress in treatment outcomes among the group of adolescent and young adult (AYA) patients with cancer is that the biology is different from the corresponding diseases in younger and older individuals, not only within the type of cancer but also within the patient. Evidence has existed for some time that colon cancer is more aggressive and has a poorer prognosis in AYA patients than in older adult patients. [1] [2] [3] However, the biologic basis and clinical ramifications of this observation are still incompletely defined. Some of the best evidence for a unique biology for AYA colon cancer compared with older adult colon cancer includes more advanced tumor stage at diagnosis, a greater frequency of mucinous histology and signet ring cells, high microsatellite instability (MSI-H), and mutations of mismatch-repair (MMR) genes in AYA patients with colon cancer. [4] [5] [6] In addition, some studies suggest a lower frequency of Kirsten rat sarcoma virus oncogene (KRAS) mutations, reduced frequency of 17p and 18q loss of heterozygosity, and lower p53 protein levels in AYA colon cancer tumors compared with those from adults. 7, 8 Several publications within the last 2 decades support the observation of poorer clinical outcomes for AYAs with colon cancer compared with older adults, even when they are placed on similar clinical treatment protocols. In some studies, those patients with nonmucinous tumors displayed a distinct survival advantage over those who had tumors that displayed a mucinous histology. 9 Other studies have demonstrated that MSI-H frequency is greater among AYA patients who have colon cancer, with greater percentages of mucinous tumors than microsatellite-stable (MSS) tumors. One study also revealed no difference between MSI and MSS subgroups with respect to family history of colon cancer, suggesting that MSI may result from acquired rather than inherited genetic defects. 10 These data suggest that colon cancer among the AYA age group may be associated with unique clinical and biologic properties. A syndrome associated with defects in MMR genes results in young age of onset colon cancer in the absence of polyposis. Lynch syndrome, also sometimes referred to as hereditary nonpolyposis colon cancer (HNPCC), is an autosomal-dominant syndrome associated with an approximately 70% lifetime risk of colon cancer (often right-sided) and a 50% to 70% risk of endometrial cancer. 11 The autosomal-dominant form is caused by heterozygous mutations in 1 of 4 MMR genes (mutS homolog 2 [MSH2]; mutL homolog 1 [MLH1]; MSH6; or PMS2) and is associated with colon cancer beginning as early as the mid-teens and extending throughout the adult years. A retrospective review of genetic counseling data from 193 patients aged < 50 years demonstrated that those without a hereditary syndrome more frequently presented with metastatic disease, whereas those with a syndrome presented at an earlier stage. 12 Two National Cancer Institute-sponsored workshops have identified AYA colon cancer as a candidate for further analysis to explore a possible unique biology and/or clinical course for this disease compared with that in adults. 13, 14 Relatively few molecular genetic studies have been conducted in this age group, perhaps because these patients are few in number, and tissue samples are difficult to procure. Recent work by The Cancer Genome Atlas (TCGA) study has provided data on genes that are frequently mutated in adult colon cancer. 15 That and other studies have identified several genes that exhibit amplification and elevated expression in adult colon cancer, including insulin-like growth factor 2 (IGF-2). 16 Consensus gene sets that exhibit mutations in adult colon cancer have also been identified. 17, 18 These data provide a baseline for pathway analysis that could direct us toward novel signaling pathways in AYA colon cancers. To begin to elucidate any biologic distinctions between adult and AYA colon cancers, we conducted whole-exome sequencing (WES) on a cohort of 30 adult, 30 AYA, and 2 pediatric colon cancers and detected differences in mutational patterns between AYA and adult samples. We also performed transcriptome analysis using RNA sequencing (RNASeq) on a subset of these samples for which RNA was available to confirm the mutations detected by WES and to investigate expression anomalies.
MATERIALS AND METHODS

Colon Cancer Tissue Samples
Most adult and AYA colon cancer tissues were provided by the Mayo Clinic (Rochester, MN; L.A.B.). Additional AYA colon cancer tissue samples were provided by St. Jude Children's Research Hospital (Memphis, TN; W.L.F.). Adult and AYA colon cancer samples were procured as 10-lm, formalin-fixed, paraffin-embedded (FFPE) tissue sections with an adjacent hematoxylin-andeosin (H&E)-stained slide for examination of the tumor pathology. The H&E-stained slides were scanned into an Aperio imaging system (Leica Biosystems, Wetzlar, Germany) for archiving and later analysis. A pathologist examined the H&E-stained slides to identify regions that contained 70% tumor tissue content. These regions of tumor were then macrodissected and placed into barcoded tubes before nucleic acid isolation. Adult colon tumors were from patients ages 61 to 90 years (mean age, 78 years), and AYA colon cancers were from patients ages 19 to 39 years (mean age, 33 years). Two pediatric samples from patients ages 13 and 14 years also were analyzed (the mean patient age was 31 years when these 2 patients were included). The sample set consisted of 29 males and 33 females. Anatomic sites of the tumors in our sample set included sigmoid, cecum, ascending colon, descending colon, transverse colon, hepatic flexure, and splenic flexure and are presented in Supporting Table 1 (see online supporting information). All tumors were identified as adenocarcinoma, and some samples had evidence of mucinous or signet ring histology. Information on the demographic distribution of the samples is provided in Supporting Table 2 (see online supporting information).
Nucleic Acid Isolation and DNA Shearing DNA and RNA were isolated using the Qiagen Allprep FFPE kit (Qiagen, Hilden, Germany). 19 Briefly, the macrodissected FFPE tissue was deparaffinized in xylene. The resulting pellet was then digested with proteinase K for 15 minutes with shaking (600 revolutions per minute) at 56 8C. The solution was centrifuged, and the supernatant transferred to a new tube. The RNA-containing supernatant was then digested for a further 15 minutes at 80 8C, deoxy ribonuclease (DNase) digested, and purified to completion using Qiagen RNeasy MinElute spin columns. The DNA-containing pellet was digested for 1 hour at 56 8C (with shaking) followed by a 2-hour digestion at 90 8C (without shaking). The supernatant was treated with ribonuclease (RNAse) and purified to completion using Qiagen QIAamp MinElute spin columns. After completion, RNA and DNA concentrations were determined using the DropSense96 spectrophotometer (Trinean NV, Gentbrugge, Belgium) and stored at 280 8C for future use. The quality of DNA assessed using the KAPA quantitative polymerase chain reaction method (KAPA Biosystems; Roche Holding AG, Basel, Switzerland). 20 The results indicate a range of values for the Q129/Q41 ratio from 0.110 to 0.652, and the control CEPH cell line had a ratio of 1.01. However, we observed, that even DNA samples with Q129/Q41 ratios as low as 0.110 yielded libraries of sufficient quality and complexity for whole-exome capture and sequencing. In addition, AYA and adult samples were intermixed on the same flow cell and sequencing run, as opposed to sequencing AYA samples on 1 run and adult samples on another. This was done to avoid batch effects from 1 group compared with the other. DNA was re-quantified using a Qubit Fluorometer (Life Technologies/Thermo Fisher Scientific, Waltham, MA) and was sheared on a Covaris LE220 Focus Ultrasonicator device (Covaris, Inc, Woburn, MA) at a duty cycle of 10%, an intensity of 5 at 200 cycles per burst for 6 cycles (at 60 seconds each), and at a temperature from 4 8C to 7 8C; and postshear cleanup was performed using Agencourt beads (Beckman Coulter Inc, Jersey City, NJ) in preparation for DNA library construction.
DNA Library Construction, Whole-Exome Capture, and Sequencing DNA library construction was performed according to the Agilent SureSelect Target-Enrichment System (Agilent Technologies, Santa Clara, CA) for the Illumina PairEnd Sequencing Library Protocol with modifications (Illumina Inc, San Diego, CA). Briefly, 500 ng input DNA was used for each sample and sheared as described above. Samples were then purified using Agencourt AMPure XP beads (Beckman Coulter Inc) and quality assessed using an Agilent 2100 Bioanalyzer system. The ends were repaired, the product was bead-purified, and A bases were added to the 3 0 ends of the DNA fragments to generate an A-base overhang. The product of this reaction was again bead purified; and indexing-specific, paired-end adaptors were attached to it using T4 ligase. The product of this reaction was bead-purified, and the adaptor-ligated library was amplified using Herculase II fusion DNA polymerase (Agilent Technologies). The postamplification product was bead purified and assessed for quality using the Agilent Bioanalyzer system. The library was then hybridized with the SureSelect Human All Exon 50-Mb library to perform exome capture (Agilent Technologies). Hybridization was performed 65 8C for 16 hours, and the exome capture library was enriched using magnetic Dynabeads (Agilent Technologies). Index tags were added by posthybridization amplification. Exome capture libraries were sequenced on an Illumina HiSeq 2000 system using the Illumina standard operating procedure with modifications (Illumina Inc).
Exome Sequence Data Analysis
FASTQ files were used to align the sequence to the human genome 19 release; and mapping, mapping calibration, small variant calling, and postprocessing were performed as described in Supporting Figure 1 (see online supporting information). The data were filtered for nonsynonymous mutations, mutations that displayed >0.01 frequency in the 1000 genomes database, with a total coverage 20, variant coverage 4, a GATK quality score 100 (Broad Institute, Cambridge, MA), and a variant allele frequency 20%.
RNASeq Analysis
RNA libraries were prepared according to the manufacturer's instructions for the TruSeq Stranded Total RNA Sample Prep Kit (Illumina Inc). The liquid-handling Eppendorf EpMotion 5075 robot (Hamburg, Germany) was used for all AMPure bead clean up. Reversetranscription, A-tailing reaction, and adaptor-ligation steps were manually performed. Briefly, 1 lg of total RNA was used as input for ribosomal depletion by RiboZero Gold (Illumina Inc) to remove both cytoplasmic and mitochondrial ribosomal RNA. First-strand complementary DNA (cDNA) synthesis was performed using SuperScript III reverse transcriptase (Thermo Fisher Scientific), actinomycin D, and random primers. Second-strand cDNA was synthesized using deoxyuridine triphosphate. The stranded cDNA ends were A-tailed and ligated with index adaptors for multiplex sequencing. The adaptermodified DNA fragments were enriched by 15 cycles of polymerase chain reaction using primers from Illumina Sample Prep Kit. The concentration and size distribution of the libraries were determined on an Agilent Bioanalyzer DNA 1000 chip (Agilent Technologies). Final quantification using Qubit fluorometry (Invitrogen, Carlsbad, CA) was done to confirm sample concentration. The libraries were sequenced as 101 paired end reads on an Illumina HiSeq 2000.
Processing of RNASeq Data
The paired-end RNASeq FASTQ files were subjected to a quality check by using PRINSEQ. 22 Specifically, the GC content distribution, tag sequence identification, read quality by position, exact duplicates, and 3 0 -end poly-A/T distribution for each individual sample were observed and reviewed manually to set up optimal steps and filtering thresholds for cleaning raw FASTQ files. On the basis of Original Article the manually reviewed results, the following steps were adopted, including remove adaptor sequence, remove read pairs aligned to ribosomal RNA or transfer RNA, remove low-average-quality reads (Phred score 30), and trim low-quality (Phred score 30) base pairs from the 3 0 end. The cleaned FASTQ files were analyzed by using the RNA-Seq Unified Mapper (RUM) (comparative analysis of RNA-Seq alignment algorithms and the RUM; University of Pennsylvania, Philadelphia, PA), which aligns RNA short reads by mapping with the Bowtie aligner (Johns Hopkins University, Baltimore, MD) against both genome and transcriptome. The information is merged, and nonmappers are processed by BLAT (Genome Browser, University of California-Santa Cruz, Santa Cruz, CA) to do gapped mapping. BLAT and Bowtie mappings are merged for the final alignments. Features are quantified separately for uniquely and nonuniquely mapped reads, and junction files are produced.
Differential Expression Analysis
Uniquely mapped reads from RUM workflow were used for differential expression analysis. Differences in expression between young and adult-onset colon cancers were tested using differential expression analysis for sequence count data (DESeq), 23 which tests for differential expression by using the negative binomial distribution and a shrinkage estimator for the distribution variance.
RESULTS
Tissue Samples and Quality Metrics
Adult colon tumors from patients ages 61 to 90 years (median age, 78 years) and AYA colon cancers from patients ages 19 to 39 years (median age, 33 years) were analyzed for mutational differences using WES. Two pediatric samples from patients ages 13 and 14 were also included in the analysis and were counted as AYA samples. DNA isolated from the CEPH cell line NA12753 was used as a reference for DNA sequencing. The sample designations, patient age and sex, along with tumor location, histology, tumor grade, and TNM staging information for each of the samples, are provided in Supporting Table 1 (see online supporting information).
Somatic Mutational Comparison of Adult and AYA Colon Cancer
Complete exome sequencing data were obtained from 30 adult, 30 AYA, and 2 pediatric colon tumor samples using the Agilent SureSelect Target Enrichment System for the Illumina Pair-End Sequencing Library protocol and sequencing on the Illumina HiSeq 2000 platform.
The variant call formats were analyzed as described above (see Materials and Methods), and a comparison was made of somatic mutational profiles between the AYA and adult colon cancer tumors. Because neither germline nor normal tissues were available from these patients, we selected the top 20 most frequently mutated genes in colon adenocarcinoma, as cited in the Catalogue of Somatic Mutations in Cancer (COSMIC). 24 We then compared the mutation frequency for these genes in our adult samples with those in the COSMIC database and in The Cancer Gene Atlas (TCGA) colorectal cancer database. 15 The results are presented in Table 1 , and MLH1) exhibited less correspondence with the mutation frequencies reported in the TCGA data. Performing the same comparison with data from COSMIC, mutational frequencies were less consistent in the adult samples, because only 8 genes (TP53, PIK3CA, CREBBP, ARID1A, KMT2D, CDH1, TRRAP, and MLH1) closely corresponded to the frequencies reported in the COS-MIC data, and 4 genes (KRAS, FBXW7, BRAF, and CARD11) had mutational frequencies within 50 percentile points of the frequencies reported in the COSMIC data. The other 8 genes (APC, ATM, PTEN, SMAD4, RB1, KIT, PTCH1, and NF1) displayed little correlation between the mutational frequency reported in the COS-MIC database and in our adult samples. Some of the discrepancy between our results and these 2 databases may be because the TCGA data are from >200 colon cancer samples, and the COSMIC data are derived from many hundreds of samples, whereas our adult data consisted of only 30 samples. Also, the COSMIC database includes cell line and xenograft sources (which are included in our analysis); and, in some cases, tumor samples may be contaminated with germ-line variants. Despite this, in general, the mutational frequencies for these genes in our adult colon cancer samples were consistent with those reported in the COSMIC and TCGA data for adult colon cancer tumors.
In our sample sets, the statistical significance of differences in gene mutation frequency in AYA versus adult colon cancers was calculated using the Fisher exact test. 25 Initially, there were 43 genes in our study that met the criteria for exhibiting a significantly greater mutational frequency in AYA versus adult colon cancers (P .05) and, based on gene function or evidence from the literature, had a potential role in colon cancer. The names and known functions of these 43 genes are listed in Table 2 , with the functions derived from the GeneCards database. 26 Of these genes, 13 had a P value < .01 (Fisher exact test) and thus exhibited the greatest differential in mutation frequency between the AYA and adult groups. These include roundabout receptor 1 (ROBO1), SIPAL1, MYCBP2, MED12L, BRCA2, MSH2, COL16A1, DNAJC2, EPHA3, laminin, b2 (LAMB2), mitogen-activated protein kinase kinase kinase 3 (MAP3K3), microcephalin 1 (MCPH1), and rat sarcoma guanyl-releasing protein 3 (RASGRP3). Most of these mutations were nonsynonymous missense, stop-gain, or frameshift mutations that were damaging. For example, ROBO1 exhibited a mutation in 32% of the AYA colon cancer samples and in 0% of the adult samples. Of the 10 AYA tumors that exhibited ROBO1 mutations, 7 had at least 1 damaging mutation, as predicted by SIFT analysis, 27 whereas 2 had mutations that were predicted to be tolerated, and 1 had a mutation for which the impact on the protein was not available. ROBO1 has been implicated as a potential tumor-suppressor gene in a study of human breast, renal cell, and small cell lung cancers in which the promotor hypermethylation inactivation of ROBO1 was associated with these cancer types. 28 Another 13 genes, including BCORL1, PTCH1, ARHGAP31, DEPDC5, DMTF1, EFS, mucin 13 (MUC13), PGR, checkpoint clamp component B (RAD9B), TAXIBP1, TONSL, PH domain and leucine-rich repeat protein phosphatase 1 (PHLPP1), and topoisomerase I binding, arginine/serine-rich, E3 ubiquitin (TOPORS) had Fisher exact P values from .01 to < .02. There were 8 genes with P values from .02 to < .03 (SIGLEC10, ADAP2, GRP133, AMPH, CTNND1, FUS, GRPR, and TLE1]), 7 genes with P values from .03 to < .04 (ATM, PI3C2G, HIPK2, NF1, ataxia telangiectasia and Rad3 related [ATR], KIT, and PTEN), and 2 genes with P values between .04 and .05 (FBXW7 and INPP5F).
Association With AYA Colon Cancer
Although all of the genes listed in Table 2 have the potential to be associated with AYA colon cancer, several are of particular interest based on their more frequent Original Article mutation in AYA compared with adult colon cancers and their known functional role in tumorigenic pathways. Focusing on the genes that display the greatest statistically significant difference in mutation frequency between AYA and adult colon cancer samples (P < .01), MYCBP2 encodes a protein that mediates protein ubiquitination and may regulate transcriptional activation of MYC. 29 This gene displays a mutation frequency of 52% in AYA colon cancer samples and only 7% in adult samples. This compares with a mutation frequency of 7% for this gene in the TCGA database and 8% in the COSMIC database for adenocarcinoma of the colon. BRCA2 is a tumor-suppressor gene involved in double-stranded DNA repair 30 and displays a mutation frequency of 39% in AYA colon cancer and 3% in adult colon cancer compared with mutation frequencies of 5% and 11% in TCGA and COSMIC, respectively. MSH2 encodes a protein involved in postreplicative DNA mismatch repair 31, 32 and is known to be more frequently mutated in AYA colon cancer and in patients with Lynch syndrome.
12 MSH2 had a mutation frequency of 39% in our AYA colon cancer sample set and only 3% in the adults, whereas the frequencies displayed for TCGA and COSMIC databases were 3% and 8%, respectively. MAP3K3 encodes a tyrosine kinase that regulates stressactivated protein kinase and extracellular signalregulated protein kinase pathways by activating SEK (dual-specificity mitogen-activated protein kinase kinase) and MEK1/2 (mitogen-activated protein kinase kinases 1 and 2), respectively. 33 It was mutated in 26% of the current AYA colon cancer samples, in 0% of the current adult samples, and in only 2% of samples in TCGA and COSMIC databases. MCPH1 encodes microcephalin 1, which arrests cell division at the G2/M checkpoint through cyclin-dependent kinase 1 phosphorylation in response to DNA damage. 34 This gene was mutated in 26% of our current AYA colon cancer samples, in 0% of our current adult samples, and in only 3% and 2% in TCGA and COSMIC databases, respectively. The last gene in this category is RASGRP3, which encodes a RAS activator (RAS guanyl-releasing protein 3) 35 and is mutated in 26% of AYA samples and 0% of adult samples. Corresponding mutation rates for this gene in TCGA and COSMIC databases are 3% and 2%, respectively. These results and those for other genes of interest with statistically significant differences in mutational frequency between AYA and adult colon cancers (from P 5 .01 to P 5 .05) that may be involved in colon cancer are reported in Table 3 .
There are several other genes known to be involved in colon cancer that exhibited some degree of mutation in our sample set and are listed in Table 4 . Of these, APC exhibited the greatest frequency of mutation in both AYA and adult samples, with at least 1 mutation in this gene identified in 75% of AYA samples and 73% of adult samples. Both MSH2 36,37 and MSH6, 2 genes involved in DNA mismatch repair, display large differences in mutation frequency between AYA and adult colon cancer. These genes are known to exhibit increased mutational frequency in AYA colon cancer. The mutation frequencies in our adult colon cancer samples aligned well with those reported in TCGA and COSMIC databases in this gene set (Table  4) , supporting the validity of our sequencing results, although DNA from control tissues were not available for sequencing. Because the majority of tumors in these databases are likely from adult patients, this provides additional confidence that the increased mutation frequencies we observed in our AYA samples are not sequencing artifacts. The PTCH1 gene, which encodes the receptor for the tumor-suppressor sonic hedgehog (Tables 2 and 4) , also exhibited a statistically significant difference in mutation frequency between AYA and adult colon cancer. The results discussed above are based only on mutation frequency as determined by WES. To confirm these results, we performed transcriptome analysis using RNASeq as described above (see Materials and Methods). However, only 17 of the AYA colon cancer samples and 14 of the adult samples had enough high-quality RNA on which to perform RNASeq. Of the 43 genes in Table 2 that were identified by WES as being more frequently mutated in AYAs compared with adults, 11 were confirmed by RNASeq as being more frequently mutated at the same nucleotide positions that were reported in the exome sequence data. The results of this analysis are provided in Table 5 . The data for these 11 genes was then subjected to the additional restrictions of only counting damaging mutations. When this additional restriction was applied, only 5 genes maintained a significantly increased frequency of mutation for AYA samples compared with adult samples: MYCBP2, BRCA2, PHLPP1, TOPORS, and ATR. Detailed information on the mutations detected in these 5 genes, along with DNA polymerases e, catalytic subunit (POLE), is presented in Supporting Table 3 (see online supporting information). The genes of interest for AYA colon cancer, as defined by our analysis, can be parsed by 3 levels of rigor, with level 1 indicating genes Original Article that were identified as being more frequently mutated in AYA patients based only on WES and a Fisher exact P value < .05; level 2, genes that met level 1 criteria and were validated by RNASeq; and level 3, genes that met level 1 and 2 criteria and contained damaging mutations. For level 3, the cutoff was arbitrarily set at an AYA mutational frequency >20%, leading to the identification of 5 genes. However, a less stringent cutoff would allow the inclusion of several other genes, including POLE. There was no discernable correlation between mutation frequency and either tumor location or patient sex for the AYA samples.
DISCUSSION
The incidence of both colon cancer and rectal cancer is increasing in AYAs 39, 40 ; however, current colorectal cancer screening guidelines do not provide for early detection screening unless a young individual has a family history of young-onset colorectal cancer or a known hereditary genetic risk. 41 Recognition of the genetic underpinnings of AYA colon and rectal cancer is crucial for the development of enhanced colorectal polyp and cancer screening and for targeted treatments that may differ from those best suited to the AYA patient with colorectal cancer. From our study of AYA and adult colon cancers, some genes are mutated with significantly greater frequency in AYA colon cancers compared with both our adult sample set and the mutational data reported in TCGA and COSMIC. On the basis of our analysis of mutations identified by exome sequencing and confirmed by RNASeq, the strongest evidence for greater mutational frequency in AYA colon cancers compared with adult colon cancers is for the genes MYCBP2, BRCA2, PHLPP1, TOPORS, and ATR. This is not to suggest that any of the other candidate genes listed in Table 2 are not more frequently mutated in AYA but, rather, that we do not have compelling RNASeq confirmatory evidence for this in the subset of samples for which RNA was available.
In this regard, several of the genes reported in Table 2 are involved in DNA repair pathways. We observed that 39% of AYA samples contained at least 1 mutation in the DNA mismatch-repair gene MSH2, whereas only 3% of adult samples did. Although this was expected, because MSI is present in many AYA colon cancers, we also observed a greater frequency of mutations in AYA patients for genes associated with other DNA repair pathways, including BRCA2 (AYA samples, 39%; adult samples, 3%) and RAD9B (AYA samples, 22%; adult samples, 0%), and the cell-cycle checkpoint kinases ATM (AYA samples, 35%; adult samples, 7%) and ATR (AYA samples, 48%; adult samples, 13%). Therefore, mutations in DNA-repair genes other than the MMR genes MLH1, MSH2, and MSH6 may be important to the biology and development of colon cancer in the AYA patient population. The WES data (Table 2) demonstrate that MUC13 was mutated in 23% of AYA cancers and in 0% of adult cancers, is consistent with the mucinous nature of many AYA colon cancers 42 : however, altered Muc13 expression was not evident in the RNASeq data.
In 2016 a study published by Kothari et al, a targeted panel of 1321 genes was used to perform exome sequencing on colorectal cancer tumors from 195 older patients (aged 65 years) and 30 younger patients (aged 45 years). In that study, 2 genes, FBXW7 and POLE, had significantly greater mutation rates in younger patients. 43 However, only 17 of the 43 genes identified in our current study as having a greater mutation frequency in AYA patients were on that panel of 1321 genes. Within the aforementioned study's validation set of 21 younger patients, none of the other 26 genes in our panel were identified as more frequently mutated in younger patients. Although the study by Kothari and colleagues contained a larger cohort of older patients than ours, the initial set of younger patients (excluding the 21-patient validation set) was the same (N 5 30). It is noteworthy that the age of the younger patient cohort in the Kothari et al study ranged from 30 to 45 years, with a median age of 42 years (which is technically outside the upper limit of 39 years for AYA patients), whereas the age of our AYA cohort ranged from 19 to 39 years, with a median age of 33 years. Thus, our younger cohort was more representative of AYA patients. Despite these differences, we have also demonstrated that FBXW7 and POLE were mutated more frequently in the younger cohorts than in adults. Although FBXW7 was at the edge of statistical significance based on WES data and was not confirmed by RNASeq, POLE is included as 1 of the genes in Table 5 . Whereas POLE exhibited a smaller difference in mutational frequency between AYA and adult colon cancers, after filtering for validation by RNASeq and for damaging mutations, POLE achieved the same frequency of mutation in AYA samples as PHLPP1, TOPORS, and ATR. Thus, we have included it in Supporting Table 3 (see online supporting information), which describes the nature of the mutations in the genes of interest. Two POLE mutations identified in our AYA samples-P286R (a proline to arginine mutation at position 286) and P697A (a proline to alanine mutation at position 697) (for details, see Supporting Table 3 in the online supporting information)-overlap with the POLE mutations identified in young patients from the study by Kothari et al. 43 The objective of this study was to provide the research community with an initial and very preliminary landscape of genes that appear to display a greater mutational frequency in AYA colon cancer compared with their adult counterparts. The sample set in our study is small and was derived mostly from a single region of the country. Further scrutiny in larger, more comprehensive sample sets may eliminate many of the genes identified here from contention and prove that others not identified here are more significantly associated with AYA colon cancer. However, the dissemination of these data may eventually reveal gene mutation profiles that demonstrate biologic and/or clinical differences between the disease in AYA and adult patients that can then be exploited to better understand AYA colon cancer and better treat these patients. The 5 genes cited here as exhibiting significantly greater mutational frequency in AYA colon cancer compared with adult colon cancer may not all be informative in distinguishing the characteristics of AYA colon cancer and may not even play a role in colon cancer development. Determining the validity of these findings and deciphering their role in AYA colon cancer development and progression will require larger studies that include a germline sequence analyses and the inclusion of an extensive validation set. Eventually, focused in vivo and in vitro studies on specific genes will be required to discern the functional role of their products in AYA colon cancer. Only then can we begin to understand the biologic
